Cite
Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K
MLA
Salas Maribel, et al. “Health and Economic Impact of Combining Metformin with Nateglinide to Achieve Glycemic Control: Comparison of the Lifetime Costs of Complications in the U.K.” Cost Effectiveness and Resource Allocation : C/E, vol. 2, Apr. 2004, p. 2. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....988ef7a3e2b717da9dca073fe743ee43&authtype=sso&custid=ns315887.
APA
Salas Maribel, Ward Alexandra J, Caro J Jaime, & Owens David. (2004). Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K. Cost Effectiveness and Resource Allocation : C/E, 2, 2.
Chicago
Salas Maribel, Ward Alexandra J, Caro J Jaime, and Owens David. 2004. “Health and Economic Impact of Combining Metformin with Nateglinide to Achieve Glycemic Control: Comparison of the Lifetime Costs of Complications in the U.K.” Cost Effectiveness and Resource Allocation : C/E 2 (April): 2. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....988ef7a3e2b717da9dca073fe743ee43&authtype=sso&custid=ns315887.